Work

Specific Immunotherapy Using a Recombinant Vaccinia Virus Expressing Human Carcinoembryonic Antigen

Year: 1993

Type: article

Abstract: Carcinoembryonic antigen (CEA) is a 180-kD glycoprotein expressed in human colorectal, gastric, pancreatic, breast, and non-small cell lung carcinomas.Although CEA is not specific for these cancers, it has clinical utility in the surveillance of the postoperative patient following primary tumor resection.The development of monoclonal antibodies (MAbs) directed against CEA has led to improvements in the diagnostic imaging of these primary tumors and the immunolocalization of metastatic disease.Several recent approaches, including antiidiotype antibodies and radiolabeled and drug-conjugated MAbs, have prompted interest in targeting CEA for immunotherapy.Carcinoembryonic antigen is generally considered to be weakly immunogenic in humans.Little evidence exists for humoral or cellmediated immunity to CEA in normal or cancer patients.To potentiate the immunogenicity of CEA, we constructed a recombinant vaccinia virus expressing human CEA (rV-CEA) and then evaluated its ability to prevent and inhibit the growth of tumors expressing CEA.

Source: Annals of the New York Academy of Sciences

DOI: 10.1111/j.1749-6632.1993.tb44034.x

Authors: JUDY KANTOR, SCOTT ABRAMS, KARI IRVINE, PHILIP SNOY, HOWARD KAUFMAN, JEFFREY SCHLOM

Institutions: National Cancer Institute, United States Food and Drug Administration

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2004497545

FWCI: 0.614

Cites: 4

Cited by: 28

Related to: 10